Skip to Content
Merck
All Photos(4)

Documents

P4394

Sigma-Aldrich

cis-Diammineplatinum(II) dichloride

≥99.99% (trace metal analysis), crystalline, anti-neoplastic agent drug

Synonym(s):

cis-Dichlorodiammine platinum(II), cis-Platinum(II) diammine dichloride, Cisplatin

Sign Into View Organizational & Contract Pricing


About This Item

Linear Formula:
Pt(NH3)2Cl2
CAS Number:
Molecular Weight:
300.05
EC Number:
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

product name

cis-Diammineplatinum(II) dichloride, crystalline

form

crystalline

color

yellow

mp

270 °C (lit.)

antibiotic activity spectrum

neoplastics

Mode of action

DNA synthesis | interferes

originator

Corden

SMILES string

N.N.Cl[Pt]Cl

InChI

1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2

InChI key

LXZZYRPGZAFOLE-UHFFFAOYSA-L

Looking for similar products? Visit Product Comparison Guide

Application

cis-Diammineplatinum(II) dichloride has been used:
  • in cell viability measurement in cochlear explants
  • in the inhibition of cell proliferation and chemosensitivity in ovarian cancer cell lines
  • in MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide] cell viability assay in oral squamous cell carcinoma

Biochem/physiol Actions

Potent chemoimmunotherapeutic drug; stimulates the immune responses by activating macrophages and other cells of the immune system. Cisplatin-treated macrophages show increased antigen presentation function in vitro. Treatment increased cellular NF-κB content and translocation in macrophages. Cisplatin effects are regulated by kinases, phosphatases, and Ca2+/calmodulin. Forms cytotoxic adducts with the DNA dinucleotide d(pGpG), inducing intrastrand crosslinks.
Potent platinum-based antineoplastic agent. Forms cytotoxic adducts with the DNA dinucleotide d(pGpG), inducing intrastrand cross-links.

Features and Benefits

This compound is a featured product for Apoptosis research. Click here to discover more featured Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the Caspases page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Corden. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Storage and Stability

This product is to be stored in room temperature. Keep the product tightly closed in a well-ventilated place. Dry. Please view the Safety Data Sheet for more information.

Pictograms

Skull and crossbonesHealth hazard

Signal Word

Danger

Hazard Classifications

Acute Tox. 2 Oral - Carc. 1B - Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

6.1B - Non-combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Calpain system protein expression and activity in ovarian cancer
Zhang S, et al.
Journal of Cancer Research and Clinical Oncology, 1-17 (2018)
Role and regulation of proapoptotic Bax in oral squamous cell carcinoma and drug resistance
Alam M, et al.
Head & Neck (2018)
Lin Hou et al.
Life sciences, 232, 116561-116561 (2019-06-28)
The poor prognosis of ovarian cancer is mainly caused by chemotherapy resistance. Studies show that the Bcl-2 inhibitor ABT737 can significantly improve the effect of cisplatin and induce mitochondrial pathway apoptosis. However, the mechanism of ABT737 increases sensitivity to cisplatin
Yi-Long Wu et al.
The Lancet. Oncology, 14(8), 777-786 (2013-06-21)
The results of FASTACT, a randomised, placebo-controlled, phase 2 study, showed that intercalated chemotherapy and erlotinib significantly prolonged progression-free survival (PFS) in patients with advanced non-small-cell lung cancer. We undertook FASTACT-2, a phase 3 study in a similar patient population.
Vicente Fresquet et al.
Blood, 123(26), 4111-4119 (2014-05-03)
Acquired resistance to targeted drugs is emerging as an obstacle to successful cancer treatment. Recently, a BCL2-selective BH3 mimetic termed ABT-199 showed promising therapeutic results in BCL2-dependent tumors. Based on its high affinity for BCL2, we studied potential mechanisms conferring

Articles

Cell cycle phases (G1, S, G2, M) regulate cell growth, DNA replication, and division in proliferating cells.

Cell cycle phases (G1, S, G2, M) regulate cell growth, DNA replication, and division in proliferating cells.

Cell cycle phases (G1, S, G2, M) regulate cell growth, DNA replication, and division in proliferating cells.

Cell cycle phases (G1, S, G2, M) regulate cell growth, DNA replication, and division in proliferating cells.

See All

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service